QIAGEN announces start of share repurchase for up to $100 million
Nov 11 2020

QIAGEN announces start of share repurchase for up to $100 million

Venlo, the Netherlands, November 11, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has commenced a share repurchase of up to $100 million as authorized in a repurchase program already announced on May 6, 2019.

In the period between today and December 17, 2020, at the latest, up to $100 million of QIAGEN shares (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) are planned to be repurchased through a financial institution commissioned by the Company exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). Based on the closing price on Tuesday, November 10, 2020, this represents a repurchase volume of approximately two million shares.

“This share repurchase program reflects our confidence in QIAGEN’s growth prospects and outlook, and is a reaffirmation of our commitment to creating value for shareholders and other stakeholders,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V.

“We have a very healthy balance sheet that enables a disciplined capital deployment policy to support QIAGEN’s business expansion while also increasing returns to shareholders,” said Roland Sackers, Chief Financial Officer of QIAGEN N.V.

QIAGEN will provide regular updates on the progress of the repurchase program in the Investor Relations section at www.qiagen.com.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.



Share this page